Major side effects occur after coronary syndrome

Published Date: 13 Mar 2023

OSA itself predicted the incidence of MACCE in non-obese patients.

Read Full News

Todays Updates


CHEST 2026 Preview: Late-Breakers to Watch Out For


CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?


Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli


New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio


The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio


New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD


The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH


A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Todays Updates


CHEST 2026 Preview: Late-Breakers to Watch Out For


CHEST 2026 Preview: Late-Breakers to Watch Out For

Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?


Clinical Forum Insights: When to Escalate to Biologics in Asthma and COPD?

ELEVIDYS Shows Sustained Functional Differences vs External Controls in Older Ambulatory Duchenne Patients Louie Pasculli


New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with delandistrogene moxeparvovec, while separate findings characterized micro-dystrophin expression in children younger than 3 years.

Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy Marco Meglio


The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy.

Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis Marco Meglio


New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis Marco Meglio, Ali Habib, MD


The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression Isabella Ciccone, MPH


A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

2.

Cancer and HIV Vaccines Enter the Therapeutic Era

3.

CAR Natural Killer Cell Therapy Shows Promise in B-Cell Lymphomas

4.

Annual Cancer Report Highlights Advances, Funding Threats

5.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot